Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
PRISM BioLab Co. LTD ( (JP:206A) ) just unveiled an update.
PRISM BioLab Co., LTD reported its non-consolidated financial results for the fiscal year ended September 30, 2025, showing a significant increase in revenue by 121.6% year-over-year, despite a net loss of ¥833 million. The company’s total assets decreased, and it faced negative cash flows from operating activities, indicating ongoing financial challenges. The absence of dividend payments and an undisclosed earnings forecast for the next fiscal year suggest cautious financial management and uncertainty about future performance.
More about PRISM BioLab Co. LTD
PRISM BioLab Co., LTD is a company listed on the Tokyo Stock Exchange, operating within the biotechnology industry. The company focuses on developing innovative bio-based products and solutions, aiming to enhance health and wellness through advanced research and development.
Average Trading Volume: 211,865
Technical Sentiment Signal: Sell
Current Market Cap: Yen5.41B
Learn more about 206A stock on TipRanks’ Stock Analysis page.